Dual TTK/PLK1 inhibition has potent anticancer activity in TNBC as monotherapy and in combination.
Zanini E, Forster-Gross N, Bachmann F, Brüngger A, McSheehy P, Litherland K, Burger K, Groner AC, Roceri M, Bury L, Stieger M, Willemsen-Seegers N, de Man J, Vu-Pham D, van Riel HWE, Zaman GJR, Buijsman RC, Kellenberger L, Lane HA.
Zanini E, et al. Among authors: roceri m.
Front Oncol. 2024 Aug 9;14:1447807. doi: 10.3389/fonc.2024.1447807. eCollection 2024.
Front Oncol. 2024.
PMID: 39184047
Free PMC article.